Physician profile
Alexander Velar
NPI 1184660516
$9,553.94
in general payments reported to CMS, 2019-2025
31 companies · $1,983 in 2025
The $1,983 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $372 · 2021: $671 · 2022: $2,081 · 2023: $1,918 · 2024: $1,857 · 2025: $1,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,618 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,618.45 |
| Education | $139.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,894.97 | 2020-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $962.53 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $851.89 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Aurinia Pharma U.S., INC. | $715.30 | 2021-2025 | Lupkynis |
| Amgen INC. | $632.47 | 2019-2025 | Tavneos, Krystexxa |
| Horizon Therapeutics Plc | $487.02 | 2021-2023 | Krystexxa |
| Akebia Therapeutics INC | $439.33 | 2019-2025 | Vafseo, Auryxia |
| Opko Pharmaceuticals, LLC | $413.97 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $399.84 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $366.71 | 2022-2025 | |
| Vifor Pharma, INC. | $320.76 | 2019-2024 | Veltassa |
| Scpharmaceuticals INC. | $300.64 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $208.06 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $202.67 | 2022-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $178.66 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| One Lambda, INC. | $172.31 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.78 | 2023-2025 | Jardiance |
| Abbott Laboratories | $148.90 | 2019 | |
| Nxstage Medical, INC. | $118.63 | 2024 | |
| Mallinckrodt Enterprises LLC | $94.24 | 2019 | |
| Ardelyx, INC. | $86.54 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $83.22 | 2025 | Ozempic, Wegovy, Rybelsus |
| Kyowa Kirin, INC. | $69.48 | 2023 | Crysvita |
| Ani Pharmaceuticals, INC. | $66.71 | 2023 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $55.28 | 2021-2022 | |
| Cycle Pharmaceuticals INC | $34.67 | 2025 | Venxxiva |
| Lilly USA, LLC | $28.35 | 2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $21.70 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $17.34 | 2020 | |
| Apellis Pharmaceuticals, INC. | $13.97 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Velar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.